. Scientific Frontline: 3D DNA Structure Drives Acute Myeloid Leukemia

Monday, November 16, 2026

3D DNA Structure Drives Acute Myeloid Leukemia

Dr. Sophie Steinhäuser researching abnormal 3D DNA organization in AML cells.
Dr. Sophie Steinhäuser, together with her colleagues, was able to demonstrate that in AML with IDH1 and DNMT3A mutations, there is an abnormal spatial organisation of the DNA, which is responsible for the activation of cancer-related signalling pathways.
Photo Credit: © Kathrin Richter, UKSH

Scientific Frontline: Extended "At a Glance" Summary
: Spatial DNA Reorganization in Acute Myeloid Leukemia

The Core Concept: Researchers have discovered that common mutations in the IDH1 and DNMT3A genes alter the three-dimensional folding of DNA within leukemia cells, establishing a previously unknown global regulatory mechanism that drives the disease.

Key Distinction/Mechanism: Instead of viewing DNA strictly as a linear sequence, this research highlights how chemical modifications (methylation) at CTCF protein binding sites disrupt the formation of critical DNA loops. This spatial reorganization inappropriately activates or isolates specific genes depending on the exact mutation present.

Origin/History: This discovery builds upon prior knowledge that IDH1 and DNMT3A mutations cause abnormal DNA methylation in acute myeloid leukemia (AML), expanding the focus to how these methylation changes physically warp genome architecture.

Major Frameworks/Components:

  • Chromosomal Conformation: The complex 3D folding of DNA allows distant genetic regions to interact and regulate gene expression.
  • CTCF-Mediated Looping: CTCF-binding proteins act as anchors, creating loops that organize which DNA segments communicate.
  • Mutation-Specific Topologies: IDH1 mutations create a distinct 3D structure that upregulates the IGF1R gene, while DNMT3A mutations generate a separate topology associated with tyrosine kinase inhibitor resistance.
  • Targeted Vulnerabilities: Identifying these warped structures revealed that IDH1-mutated cells are hyper-sensitive to IGF1R inhibitors (like BMS-754807), and DNMT3A-mutated cells show sensitivity to the p38/MAPK inhibitor Ralimetinib.

Branches of Science: Molecular Oncology, Functional Genomics, Molecular Genetics, Structural Biology, and Hematology.

Future Application: The custom analytical methods developed to map these 3D structural changes pave the way for novel, highly targeted combination therapies (such as pairing Ivosidenib with IGF1R inhibitors) tailored to a patient's specific mutation topology.

Why It Matters: By proving that cancer-driving mutations fundamentally reshape the genome's physical architecture, this research provides a comprehensive new map for identifying therapeutic targets that were invisible on a linear genetic sequence.

Abnormally degenerated AML blasts stained blue among lighter surrounding blood cells.
AML blasts (stained blue, magnified 40 times): These malignantly degenerated precursor cells can displace healthy blood cells and thus disrupt the hematopoietic system as a whole.
Image Credit: © Dr. med. Lars Fransecky, UKSH

A research team from Kiel University and the University Hospital Schleswig-Holstein (UKSH) has demonstrated how certain gene mutations alter the 3D structure of DNA and can thereby activate cancer-related genes in leukemia cells.

Acute myeloid leukemia (AML) is a malignant disorder of the hematopoietic system in the bone marrow, affecting an early precursor stage of what are known as myeloid cells. In healthy people, these cells develop into red blood cells, platelets, and some white blood cells—a process that is normally strictly regulated. In people with the disease, however, these cells exhibit genetic alterations that cause them to multiply uncontrollably in the bone marrow, where they increasingly displace the healthy blood cells. This ultimately impairs the vital functions of the hematopoietic system. The exact etiology of the disease remains incompletely understood, though it is linked to various genetic alterations, including acquired somatic mutations.

Researchers from the Faculty of Medicine at Kiel University, the Department of Internal Medicine II – Hematology and Oncology at the UKSH, Campus Kiel, the Institute of Human Genetics at UKSH, Campus Lübeck, the Institute of Medical Genetics and Human Genetics at Charité - Universitätsmedizin Berlin, and the Max Planck Institute for Molecular Genetics in Berlin/Dahlem have now published a joint paper. In this study, they investigated how two common alterations in regulatory genes—mutations in IDH1 and DNMT3A—influence the three-dimensional organization of the genome in leukemia cells. The researchers were able to demonstrate that both mutations interfere with the spatial arrangement of DNA in different ways and that these changes are associated with altered activity in numerous genes, which varies depending on the mutation. This global regulatory mechanism in AML was previously unknown. The new findings by the researchers, led by Professor Claudia Baldus of the Kiel Oncology Network (KON) and the University Cancer Centre Schleswig-Holstein (UCCSH), and Professor Malte Spielmann, Head of the Institute of Medical Genetics and Human Genetics at Charité Berlin, were recently published in the prestigious journal Leukemia. The German José Carreras Leukemia Foundation, among others, had funded the underlying research.

Chromosomal DNA does not exist purely as a linear sequence; it undergoes complex spatial organization within the nucleus. This three-dimensional folding enables physical interactions between genomic regions that are widely separated on the linear sequence. Among other things, such contacts influence which genes and signaling pathways are currently active in a cell. So-called CTCF-binding proteins play an important role in this process. They can link distant regions of the DNA, thereby forming a loop from the DNA lying between them. This spatial organization can, for example, help ensure that regulatory DNA regions come into contact with specific genes in a targeted manner, while other regions remain isolated from one another.

Previous studies established that IDH1 and DNMT3A mutations alter DNA methylation—an epigenetic modification that regulates gene expression and subsequent protein synthesis. The current study now shows that these methylation changes can also occur at the binding sites of CTCF proteins and, in this way, disrupt the formation of DNA loops, leading to a global reorganization of the three-dimensional structure of the DNA. "Our results show that both mutations influence the spatial organization of the genome," explains Dr. Sophie Steinhäuser, a research associate in the Functional Genomics of Acute Leukemia research group and first author of the study. "The changes differ between AML cells with IDH1 and DNMT3A mutations, suggesting that each genetic alteration apparently gives rise to its own characteristic 3D structure." In cell models and patient samples, the researchers identified thousands of altered DNA loops for each of the two mutations. The more these loops were altered, the more pronounced the change in gene activity was. The researchers developed their own analytical method specifically for their multi-stage investigation of the complex 3D structural data and gene expression data. "This now enables us to correlate genome-wide differences in DNA looping with global changes in gene expression," emphasizes Dr. Varun Sreenivasan, a research fellow in the Molecular Human Genetics group at the Max Planck Institute Berlin/Dahlem and also first author.

These 3D changes result in far-reaching alterations in gene activation and, consequently, in the active signaling pathways, which are specific to each mutation. In AML cells with a DNMT3A mutation, the researchers found, among other things, alterations in signaling pathways associated with resistance to tyrosine kinase inhibitors, while in AML with an IDH1 mutation, signaling pathways linked to the cells’ immune response are affected.

Notably, researchers demonstrated in both in vitro models and patient samples that the IGF1R gene is situated within an altered structural loop and is significantly upregulated in IDH1-mutated cells. To determine whether targeted inhibition of IGF1R could be a potential treatment option for IDH1-mutated AML, the researchers not only compared drug response data from previously published studies but also investigated IGF1R sensitivity in the cell model. The results indeed showed that both patient data and IDH1-mutated AML cells exhibited greater sensitivity to this drug than cells without an IDH1 mutation. BMS-754807 also demonstrated a synergistic effect when combined with the IDH1 inhibitor ivosidenib, which is used in clinical practice.

As with IDH1, the researchers also identified the p38/MAPK inhibitor ralimetinib as a potential therapeutic option from samples and cell models of AML with DNMT3A mutations. "Overall, our work provides a comprehensive map of the changes in 3D DNA organization in AML with IDH1 and DNMT3A mutations," emphasizes Baldus, head of the Functional Genomics of Acute Leukemia research group at Kiel University’s Medical Faculty and director of the Department of Internal Medicine at UKSH in Kiel. "The genes and signaling pathways identified thus open up new avenues for the development of novel targeted therapies."

Funding: To this study, CDB contributed funding in the form of a project grant from the German José Carreras Leukemia Foundation (Deutsche José Carreras Leukämie-Stiftung), reference DJCLS 21 R/2022. In addition, DB contributed funding from the German Research Foundation (Deutsche Forschungsgemeinschaft), reference 413490537. Open Access funding enabled and organized by Projekt DEAL.

Published in journal: Leukemia

Title: Alterations in 3D-DNA architecture drive unique leukemic profiles in IDH1- and DNMT3A-mutant acute myeloid leukemia

Authors: Sophie Steinhäuser, Varun K. A. Sreenivasan, David Baden, Miriam Denker, Thomas Beder, Kathrin Richter, Theodor Hutter, Britta Steer, Verónica Yumiceba, Kristin Schultz, Alina Maria Hartmann, Nadine Wolgast, Simone Lipinski, Lorenz Bastian, Sonja Bendig, Monika Brüggemann, Lars Fransecky, Martin Neumann, Patricia Silva, Christoph Röllig, Malte Spielmann, and Claudia Dorothea Baldus

Source/Credit: Kiel University, and University Hospital Schleswig Holstein

Edited by: Scientific Frontline

Reference Number: ongy111626_01

Privacy Policy | Terms of Service | Contact Us

Featured Article

Room-Temperature Molybdenum Recrystallization

Raw metallic molybdenite mineral rock, the primary natural source of the chemical element molybdenum. Photo Credit: J. Adam Fenster / Univer...

Top Viewed Articles